Evidencia actual sobre la atomoxetina. Alternativa terapéutica para el trastorno por déficit de atención e hiperactividad

Vista sencilla de ítem
dc.contributor.authorVelasquez Tirado, Juan David
dc.contributor.authorPeña, Joaquín Antonio
dc.date.accessioned2020-09-11T20:41:05Z
dc.date.available2020-09-11T20:41:05Z
dc.date.issued2005
dc.description.abstractenglishAims. To conduct an updated review of the mechanisms of action, pharmacokinetics, clinical effectiveness and safety of atomoxetine in the treatment of the symptoms of ADHD. Development. Atomoxetine is the first of the group of nonstimulant drugs to be approved by the US Food and Drug Administration to treat this disorder in children, adolescents and adults. Atomoxetine has a direct effect on noradrenalin and dopamine concentrations by exerting a strong and highly selective inhibiting action on the pre-synaptic noradrenalin transporter, with a minimum affinity for other transporters and receptors. After adjustment of the dosage for body weight, the pharmacokinetic parameters are similar across all age and gender groups. Maximal plasma concentration is reached one to two hours after oral administration. Data concerning the effectiveness and safety from the clinical trials and studies reported in the literature are discussed. Conclusions. Atomoxetine is an effective and well-tolerated drug when used for the pharmacological treatment of ADHD symptoms. Despite being a drug that has only recently been developed, evidence from the large number of comparative studies that have been carried out endorse its widespread use in the treatment of this syndrome.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.33588/rn.4108.2004594
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1576-6578
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/4065
dc.language.isospa
dc.publisherViguera Editoresspa
dc.publisher.journalRevista de neurologiaspa
dc.relation.ispartofseriesRevista de neurologia, 1576-6578, Vol. 41, Nro. 8, 2005, p. 493-500spa
dc.relation.urihttps://www.neurologia.com/articulo/2004594
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2005-10-16
dc.rights.localAcceso abiertospa
dc.subject.keywordsAtomoxetinespa
dc.subject.keywordsAttention deficit hyperactivity disorderspa
dc.subject.keywordsNon-stimulant medicationspa
dc.titleEvidencia actual sobre la atomoxetina. Alternativa terapéutica para el trastorno por déficit de atención e hiperactividadspa
dc.title.translatedCurrent evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorderspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
J.D. Velásquez-Tirado, J.A. Peña_2005.pdf
Tamaño:
62.12 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos